vTv Therapeutics Inc. (VTVT) Cut to Sell at Zacks Investment Research
vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
Several other analysts also recently weighed in on VTVT. HC Wainwright started coverage on vTv Therapeutics in a research note on Monday, September 26th. They set a “buy” rating and a $13.00 target price on the stock. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price target on shares of vTv Therapeutics in a research report on Friday, August 19th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/vtv-therapeutics-inc-vtvt-cut-to-sell-at-zacks-investment-research-2.html
Shares of vTv Therapeutics (NASDAQ:VTVT) traded up 1.60% during mid-day trading on Wednesday, hitting $6.98. The stock had a trading volume of 6,652 shares. vTv Therapeutics has a 12-month low of $4.84 and a 12-month high of $8.22. The firm’s market cap is $67.64 million. The company has a 50 day moving average price of $6.46 and a 200 day moving average price of $5.91.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) earnings per share (EPS) for the quarter. Equities analysts forecast that vTv Therapeutics will post ($1.61) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock valued at $488,000 after buying an additional 22,983 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of vTv Therapeutics by 26.6% in the second quarter. BlackRock Fund Advisors now owns 202,202 shares of the company’s stock worth $1,173,000 after buying an additional 42,520 shares during the last quarter. BlackRock Investment Management LLC boosted its position in shares of vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock worth $161,000 after buying an additional 5,596 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of vTv Therapeutics by 4.1% in the second quarter. Vanguard Group Inc. now owns 288,146 shares of the company’s stock worth $1,671,000 after buying an additional 11,428 shares during the last quarter. Institutional investors own 12.84% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.